Company Overview and News

67
Morgan Stanley Calls Labs 'Safe Havens': Stocks to Watch

2018-06-04 zacks
It takes just one super deal to turn the odds in your favor. Did the clinical laboratory services market just spin the wheel of fortune? Let’s see what happened.
DB LMNX DGX MYGN AET UNH GHDX

2
LMNX / Luminex Corp. SD

2018-05-30 sec.gov
Document UNITED STATES
LMNX

2
LMNX / Luminex Corp. S-8 POS

2018-05-23 sec.gov
Document
LMNX

1
LMNX / Luminex Corp. 8-K PROXY RESULT (Current Report)

2018-05-18 sec.gov
Document UNITED STATES
LMNX

50
Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength

2018-05-09 zacks
Luminex Corporation (LMNX - Free Report) reported first-quarter 2018 earnings of 25 cents per share, beating the Zacks Consensus Estimate of 22 cents. Further, earnings rose 13.6% on a year-over-year basis.
LMNX MYGN BAX ISRG CHE

1
LMNX / Luminex Corp. 8-K (Current Report)

2018-05-07 sec.gov
Document UNITED STATES
LMNX

2
LMNX / Luminex Corp. 8-K (Current Report)

2018-04-20 sec.gov
Document UNITED STATES
LMNX

1
LMNX / Luminex Corp. DEFA14A

2018-04-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNX

1
LMNX / Luminex Corp. DEF 14A

2018-04-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNX

25
Luminex (LMNX) Product Portfolio Solid, Competition Rife

2018-03-26 zacks
On Mar 23, we issued an updated research report on Luminex Corporation (LMNX - Free Report) . The company has a broad product portfolio, which comprises advanced xMAP, xTAG and MultiCode technology. However, the company operates in the highly competitive life sciences industry.
BIO.B BIO LMNX ATHN PKI

17
RBC Says 4 Health Care Stocks Are Potential 2018 Buyout Candidates

2018-03-15 247wallst
It happens every year, and 2018 won’t be any different. Larger companies looking to add to growth, beyond that of the organic or internal variety, scan the field for purchases and acquisitions that are easy to bolt on and could add returns in a timely fashion. This year the process may even speed up some as the market sell-off that happened last month already may have put some companies in the sights of acquirers.
LMNX NUVA HAE MNK

6
Why Is Luminex (LMNX) Up 11.2% Since Its Last Earnings Report?

2018-03-14 zacks
A month has gone by since the last earnings report for Luminex Corporation (LMNX - Free Report) . Shares have added about 11.2% in that time frame.
LMNX CNA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to LMNX / Luminex Corp. on message board site Silicon Investor.

Luminex LMNX Luminex Corp. LMNX
CUSIP: 55027E102